The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for
treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical …

While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …

Metastatic or recurrent cervical cancer has a survival duration of approximately 12 months.
Thus, we review the outcomes of chemotherapy and/or novel agents for women who present …

Aims Despite recent advances in the primary and secondary prevention of cervical cancer, a
significant number of women present with or develop metastatic disease. There is currently …

Summary Background On Aug 14, 2014, the US Food and Drug Administration approved the
antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis …

Bevacizumab became the first molecular antibody to show survival benefit in advanced
cervical cancer. In the GOG-0240 (Paclitaxel and Cisplatin or Topotecan With or Without …

Cervical cancer is the third most common cancer among women worldwide and is
responsible for 275.000 deaths each year. The development of cervical cancer has been …

Historically, patients with metastatic, persistent or recurrent cervical cancer had limited
therapeutic options. Despite several Phase II/III clinical trials, the combination of cisplatin …

Uterine cervical adenocarcinoma (ADC) has been increasing in its prevalence world widely
despite the decrease of squamous cell carcinoma (SCC). It comprises nearly 20-25% of the …

The management of locally advanced cervix cancer has undergone a paradigm shift during
the last decade. Concurrent chemoradiation (CCRT)(with cisplatin alone or in combination) …